Shroom Sleep

@SquawkCNBC @CNBC @abinbev Who still drinks... beer??? 🙄

"We see moderation and healthier habits. In this case beer is fantastic because beer is low in alcohol, lower in calories," says @abinbev CEO Michel Doukeris. "Beer naturally has protein." cnb.cx/4eyVXYB

Must see👀 the main man of the Psychedelic sector will be on the podcast May 7th... youtube.com/live/9VhKdb-F8…

Just sayin... ATAI 💯

Awesome News! 🔥

HELIUM TIME! ... if you know - you Know! 😁👊

@LorkeStevie 😋

Happy Cinco de Mayo! 🎉🌮🌯

May is #MentalHealthAwarenessMonth. It’s a time for recognition of how far we’ve come and a reminder of how much more progress is needed. Over 1B people globally live with mental health conditions, many without access to effective, durable care. Addressing this unmet need requires collaboration. At AtaiBeckley, we are proud to work together across science and patient impact. Because good days shouldn’t be the exception — they should be the goal. Learn more: ataibeckley.com/our-work/patie… #MoreGoodDays #MentalHealthMatters

@C_Angermayer @hubermanlab 🔥

@hubermanlab I’d respectfully disagree on both points. They said the same about psychedelics… Broader interest tends to follow better data. And I look forward to proving you wrong on the patent angle soon 😉

You’re not going to see RCTs of BPC or epithalon or SS31 or (fill in popular peptide) because (drum roll)… there is no patent opportunity or broad enough interest. People will keep experimenting & taking however. Just be careful if you do: avoid gray and market peptides folks!

@Psymarketcapcom Soon ! 💯

people will fomo into psychedelic stocks the same way they fomo'd into AI. the question is when, not if.

@TheMindTrailer @C_Angermayer @business @g0ingmad Sounds like Pop Culture is hinting to be recruited 🤔

@C_Angermayer @business @g0ingmad Maybe ATAI should poach someone from the spravato commercialization team... Approval is merely step 1 @C_Angermayer

This excellent @business article by @g0ingmad highlights the strong success of Spravato - well worth a read. As I mentioned previously in my blog x.com/C_Angermayer/s… Spravato is indeed paving the way for psychedelic therapies. However, it is too simplistic to generalize. I strongly believe that commercial viability will determine the winners. Efficacy alone is not enough. Delivery and duration drive scalability. In my view, @ataibeckley's two lead assets - BPL-003 (5-MeO-DMT) and VLS-01 (DMT) - fit perfectly within the ~2-hour Spravato treatment window, with patient-friendly intranasal or buccal delivery. Importantly, they also could have the potential to outperform on both efficacy and the number of required treatment sessions. $ATAI

Powerful 💪 in every way!

@supercopperco Very exciting time for Super Copper Corp 👏

Our team is at the Cordillera Cobre Project this week, reviewing prospective platform locations as we advance toward our maiden drilling campaign. $CUPR.CN $CUPPF

@PsychedVantage WHOA!!

GH Research Announces Pricing of $117.5 Million Underwritten Offering $GHRS investor.ghres.com/news-releases/…

@DrMakaryFDA Yes, we can! Eliminating unnecessary delays between trials accelerates drug development and delivers new treatments to patients faster - without compromising standards. This is exactly the direction we should be taking.

Great piece from @Shea_ARK "AtaiBeckley is advancing BPL-003—an intra-nasal formulation derived from 5-MeO-DMT—in treatment-resistant depression, with positive Phase 2b results supporting a Phase 3 initiation in the second quarter of 2026.[11] With FDA Breakthrough Therapy designation, BPL-003 has the potential to achieve fast-track review under the new Executive Order." "Importantly, commercial viability for clinic-delivered mental health therapies is no longer speculative and could be ready to scale. Johnson & Johnson's Spravato is a ketamine-derived nasal spray that the FDA approved for TRD in 2019.[13] While it works through a different mechanism than classical psychedelics, Spravato not only created the playbook for clinic-administered, supervised-dosing that COMP360 and BPL-003 will follow, but also has proven its commercial potential with an annualized run rate of ~$1.9 billion.[14] COMP360 and BPL-003 are differentiated from Spravato on efficacy and dosing burden: Spravato requires twice-weekly, in-clinic dosing during the first four weeks and continued maintenance thereafter, while both Compass and AtaiBeckley’s treatments might involve only one or two dosing sessions." $ATAI $CMPS

@C_Angermayer @Psymarketcapcom 💯❤️ back to you Christian for everything you are doing to bring relief to millions of people! 👊

Fully agree. I appreciate all $ATAI shareholders, but our retail investors are, to me, the most loyal and passionate. Many of them invest not only because they believe in the financial upside, but because they truly understand our mission - and recognize that we are building a portfolio of therapeutics with the potential to be genuinely world-changing. Big love to all @ataibeckley retail shareholders ❤️

retail investors found psychedelic stocks before wall street did. remember that when institutions start buying.

Something is going on over here! .... 😁😉💯